Biotech Values

[jq1234]

That is much further down the road - these are long term trials, takes many years to run a ph3 - It needs randomized ph3 trial with surrogate endpoints. So commercial success depends on how much better than ERT alone, and how they are going to price Amigal due to VERY expensive ERT already. In that regard, co-formulation is more attractive because they can price the co-formulation competitively, but that will be even further down the road, it is not in ph1 yet.